Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
        Tocris Bioscience™ SPOP-i-6lc
 
    
    
    
    
    
    
    
    
    
    
        
                    Click to view available options
                
                
                    
                            
                                :
                            
                        
                        
                            
                                10 mg
                            
                        
                    Description
SPOP-i-6lc is a selective SPOP E3 ubiquitin ligase inhibitor (IC50 = 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively). In vitro, SPOP-i-6lc suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines. SPOP-i-6lc leads to the accumulation of tumor suppressors PTEN and DUSP7 and decreased levels of phosphorylated AKT and ERK in clear-cell renal cell carcinoma (ccRCC) cell lines.
                        
                        
                        
                        
                        
                        
                        
                        
                        
                    
                
                
                    
                
                
    
                
    
            Specifications
Specifications
| Chemical Name or Material | 1,5-Dihydro-2-imino-10-methyl-N-[2-(4-methyl-1-piperazinyl)ethyl]-5-oxo-1-[2-(2-thienyl)ethyl]-2 H-dipyrido[1,2-a:2 ',3 '-d]pyrimidine-3-carboxamide | 
| CAS | 2136270-56-7 | 
| Quantity | 10 mg | 
| Target | Ubiquitin Ligase (E3) Inhibitors | 
| Molecular Formula | C26H31N7O2S | 
| Purity | 98% | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            Spot an opportunity for improvement?Share a Content Correction
             
                                